VIVUS, Inc. (NASDAQ:VVUS) has been on a steady slide over the past five trading days — thanks to a quick rejection from its 40-day moving average one week ago. News surfaced last night that three VVUS directors have decided to not to run for re-election at the end of their term. Interestingly, short-term call open interest has almost doubled since March 24, while put open interest climbed less than 1%. As such, VVUS’ Schaeffer’s put/call open interest ratio (SOIR) fell from an annual-high reading of 1.50 to 0.88 during this time period, indicating calls now outnumber puts among options expiring within three months. Furthermore, VVUS’ 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 6.59 ranks in the 78th annual percentile, demonstrating calls have been bought to open at a faster-than-usual rate during the past two weeks. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.00 moved to $5.03 on last trade day and at the end of the day closed at $4.91. Company price to sales ratio in past twelve months was calculated as 6.25 and price to cash ratio as 1.48. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of -15.34%.
PharmAthene, Inc. (NYSEMKT:PIP) announced that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(R) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax(R) program.PharmAthene, Inc. (NYSEMKT:PIP) shares fell -7.10% in last trading session and ended the day on $1.44. PIP return on equity ratio is recorded as -310.34% and its return on assets is -128.10%. PharmAthene, Inc. (NYSEMKT:PIP) yearly performance is -34.41%.
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) has been in a downtrend over the last few trading sessions, and we believe this trend to continue and traders are advised to remain short for the time to come.The stock can also be sold at current levels with a strict stop loss at $23.85 for targets of $19.75 and $17.90.Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares moved down -9.56% in last trading session and was closed at $19.67, while trading in range of $19.61-$21.67. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) year to date performance is -54.68.
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, announced financial results for the year ended December 31, 2013. Following our initial public offering in January, we are well-positioned to drive the development of our pipeline and build on the clinical data supporting the potential for improved therapeutic benefits of our biased ligands over existing treatments,” said Maxine Gowen, Ph.D., president and chief executive officer of Trevena. “During 2014, we plan to advance our ongoing BLAST-AHF Phase 2b trial for TRV027 in acute heart failure, commence Phase 2 trials for TRV130 in moderate to severe acute pain, and complete our ongoing Phase 1 study for TRV734, our oral follow on candidate to TRV130 for acute and chronic pain. In addition, we plan to select another candidate from our proprietary ABLETM platform, a delta-opioid receptor biased ligand for CNS indications. Trevena Inc (NASDAQ:TRVN) weekly performance is -20.00%. On last trading day company shares ended up $5.80. Trevena Inc (NASDAQ:TRVN) distance from 50-day simple moving average is -24.45%. Analysts mean target price for the company is $14.80.